Product Description
Tetracyclines (tetracycline, doxycycline, minocycline, tigecycline) are a class of medication used to manage and treat various bacterial infections. Tetracyclines classify as protein synthesis inhibitor antibiotics and are considered to be broad-spectrum. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/31751095/)
Mechanisms of Action: Protein Synthesis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Topical
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Finland | France | Germany | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Italy | Jordan | Korea | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Axcan Pharma
Company Location: QUEBEC CANADA J3H 6C A8 00000
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Unknown Location
Active Clinical Trial Count: 1
Highest Development Phases
Phase 3: Pneumonia, Bacterial|Pneumonia, Ventilator-Associated
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CTR20180461 | P3 |
Not yet recruiting |
Pneumonia, Ventilator-Associated|Pneumonia, Bacterial |
None |